findmyKOL
Clinical trialNCT05421689Active, not recruitingPhase 1/PHASE2Interventional

Autologous Muscle Derived Cells for Treatment of Tongue Dysphagia

SponsorUniversity of California, DavisEnrollment66Oropharyngeal Dysphagia
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The primary objective of this double-blind, randomized, placebo-controlled, multicenter clinical trial is to evaluate the safety of AMDC-GIR during the 24 months following 2 consecutive treatments of tongue dysphagia in male and female patients who have undergone surgery and/or chemo- and/or radiotherapy for squamous cell cancer of the oropharynx.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

  • Johnathon D Anderson, PhD

    University of California Davis, Department of Otolaryngology

    Study Director
    clinicaltrials.gov ↗
  • Maggie Kuhn, MD

    University of California Davis, Department of Otolaryngology

    Principal Investigator
    clinicaltrials.gov ↗
  • Peter Belafsky, MD

    University of California Davis, Department of Otolaryngology

    Principal Investigator
    clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

2 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Uc Davis Medical Center, Department of Otolaryngology

    Sacramento, California, United States

  • Uc San Francisco Medical Center, Voice and Swallow Center

    San Francisco, California, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Autologous Muscle Derived Cells for Gastro-Intestinal Repair
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
26 May 2022
Primary completion
31 Dec 2026
Completion
31 Dec 2026
Last update posted
12 Dec 2025
Registered enrollment
66
Registry id
NCT05421689
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.